Experimental Electron Densities, Crystal Engineering and Molecular Recognition: A Supramolecular Approach to Drug Design

实验电子密度、晶体工程和分子识别：药物设计的超分子方法

• 批准号: DP0556144
• 负责人: Prof David Hibbs
• 金额: $ 56.38万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2010-10-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0556144
• 关键词: Experimental; Electron; Densities; Crystal; Engineering

GABA receptors are important therapeutic targets for the treatment of a number of disorders from memory dysfunction, to muscle spasticity and chronic pain. This project is designed to address some of the fundamental questions associated with drug/target interactions. This work will lead to a greater understanding of how the chemical structure of a drug can be tailored to produce a more effective compound. The outcomes of this program will highlight Australia as a strong contributing nation in molecular design. It is certain that the outcomes of this program will benefit Australia by providing a much greater level of understanding of the fundamental properties of molecules and how others may be rationally designed to suit a specific role.

GABA受体是治疗从记忆功能障碍到肌肉痉挛和慢性疼痛的许多疾病的重要治疗靶点。该项目旨在解决与药物/靶标相互作用相关的一些基本问题。这项工作将使人们更好地理解如何调整药物的化学结构以产生更有效的化合物。该计划的成果将突出澳大利亚作为一个强大的贡献国家在分子设计。可以肯定的是，这一计划的成果将使澳大利亚受益，因为它使人们更好地了解分子的基本性质，以及如何合理地设计其他分子以适应特定的作用。